AGL 37.84 Decreased By ▼ -0.66 (-1.71%)
AIRLINK 133.89 Decreased By ▼ -2.96 (-2.16%)
BOP 5.56 Decreased By ▼ -0.06 (-1.07%)
CNERGY 3.82 Decreased By ▼ -0.04 (-1.04%)
DCL 7.81 Decreased By ▼ -0.12 (-1.51%)
DFML 44.00 Decreased By ▼ -1.40 (-3.08%)
DGKC 87.38 Increased By ▲ 1.87 (2.19%)
FCCL 33.91 Increased By ▲ 2.31 (7.31%)
FFBL 64.86 Increased By ▲ 3.16 (5.12%)
FFL 9.97 Increased By ▲ 0.77 (8.37%)
HUBC 105.19 Decreased By ▼ -3.56 (-3.27%)
HUMNL 14.10 Decreased By ▼ -0.28 (-1.95%)
KEL 4.56 Decreased By ▼ -0.28 (-5.79%)
KOSM 7.65 Decreased By ▼ -0.09 (-1.16%)
MLCF 37.60 Decreased By ▼ -0.51 (-1.34%)
NBP 67.80 Increased By ▲ 0.80 (1.19%)
OGDC 177.00 Increased By ▲ 0.99 (0.56%)
PAEL 25.07 Decreased By ▼ -0.13 (-0.52%)
PIBTL 5.95 Increased By ▲ 0.08 (1.36%)
PPL 135.75 Increased By ▲ 2.26 (1.69%)
PRL 23.70 Decreased By ▼ -0.32 (-1.33%)
PTC 16.20 Decreased By ▼ -0.62 (-3.69%)
SEARL 65.98 Decreased By ▼ -1.77 (-2.61%)
TELE 7.09 Decreased By ▼ -0.36 (-4.83%)
TOMCL 35.44 Decreased By ▼ -0.74 (-2.05%)
TPLP 7.50 Decreased By ▼ -0.28 (-3.6%)
TREET 14.40 Decreased By ▼ -0.24 (-1.64%)
TRG 47.80 Decreased By ▼ -1.81 (-3.65%)
UNITY 25.26 Decreased By ▼ -0.25 (-0.98%)
WTL 1.26 Decreased By ▼ -0.07 (-5.26%)
BR100 9,666 Increased By 79.8 (0.83%)
BR30 28,768 Decreased By -23 (-0.08%)
KSE100 89,994 Increased By 1048 (1.18%)
KSE30 28,395 Increased By 352.5 (1.26%)
Business & Finance

EU close to vaccine supply deal with Novavax

  • "Talks with Novavax have intensified and we aim to agree the contract this week or next," one EU official said.
  • Novavax said negotiations were ongoing. A spokesman for the EU Commission declined to comment on the talks.
Published February 11, 2021

BRUSSELS: The European Union could sign a coronavirus vaccine supply deal with US manufacturer Novavax this week or next, two EU officials involved in the talks with the firm said.

The EU concluded preliminary negotiations with Novavax in December for the supply of 100 million doses and an option for another 100 million.

"Talks with Novavax have intensified and we aim to agree the contract this week or next," one EU official said.

A second EU official involved in the talks confirmed that possible timetable for a deal, but added that discussions with the company's lawyers were still under way, declining to elaborate on outstanding issues.

Novavax said negotiations were ongoing. A spokesman for the EU Commission declined to comment on the talks, but added that the EU was willing to expand its portfolio of COVID-19 vaccines.

The company's shares were up by 2.3% in premarket trade after Reuters reported that a deal with the EU was close .

Last week Europe's drug regulator said it had launched a real-time review of Novavax's vaccine to speed up potential approvals.

The vaccine is still being trialled, but preliminary data showed the vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK.

The deal, if it goes ahead, would be the seventh sealed by the EU with vaccine makers for COVID-19 shots. It already has agreements with AstraZeneca, Johnson & Johnson, Pfizer-BioNTech, CureVac, Moderna and Sanofi-GSK for a total of about 2.3 billion doses.

Comments

Comments are closed.